Early optimism in the use of GLP-1 therapies for Parkinsons disease has been tempered by the recent failure of a Phase III exenatide trial which did not show any benefits of slowing Parkinsons progression 10
Patients report stronger energy, improved appetite control, and sustainable weight management
Users start Wegovy at a dose of 0.25 mg once a week and increase the dose every 4 weeks until they reach the full dose of 2.4 mg
Learn more about how to get insurance to cover revision bariatric surgery and take the first step today
Additional markers to consider: oxidative stress markers (8-isoprostane, malondialdehyde), inflammatory markers (hsCRP, IL-6), liver function tests
Because GHK-Cu arrives as lyophilized powder reconstituted to a researcher-chosen concentration, the same target dose corresponds to different syringe volumes depending on the reconstitution choice